Land: Storbritannien
Språk: engelska
Källa: MHRA (Medicines & Healthcare Products Regulatory Agency)
Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate
Reckitt Benckiser Healthcare (UK) Ltd
A02BX
Sodium bicarbonate; Alginic acid; Aluminium hydroxide gel dried; Magnesium trisilicate
170mg ; 500mg ; 100mg ; 25mg
Chewable tablet
Oral
No Controlled Drug Status
Never Valid To Prescribe As A VMP
BNF: 01010201
OBJECT 1 GAVISCON PEPPERMINT FLAVOUR TABLETS Summary of Product Characteristics Updated 14-Mar-2016 | Reckitt Benckiser Healthcare (UK) Ltd 1. Name of the medicinal product Gaviscon Peppermint Flavour Tablets. 2. Qualitative and quantitative composition Each tablet contains sodium alginate 250 mg, sodium hydrogen carbonate 133.5 mg and calcium carbonate 80 mg. Excipients: Aspartame (E951) 3.75 mg per tablet. For excipients, see Section 6.1. 3. Pharmaceutical form Chewable tablet. An off-white to cream, slightly mottled tablet. 4. Clinical particulars 4.1 Therapeutic indications Treatment of symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion (related to reflux), for example, following meals or during pregnancy or in patients with symptoms related to reflux oesophagitis. 4.2 Posology and method of administration For oral use, after being thoroughly chewed. Adults and children 12 years and over: Two to four tablets after meals and at bedtime. Elderly: No dose modifications necessary for this age group. 4.3 Contraindications This medicinal product is contraindicated in patients with known or suspected hypersensitivity to the active substances or to any of the excipients. 4.4 Special warnings and precautions for use If symptoms do not improve after seven days, the clinical situation should be reviewed. The sodium content of a four-tablet dose is 246 mg (10.6 mmol). This should be taken into account when a highly restricted salt diet is recommended. e.g. in some cases of congestive cardiac failure and renal impairment. Each four-tablet dose contains 320 mg (3.2 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Due to its aspartame content this product should not be given to patients with phenylketonuria. 4.5 Interaction with other medicinal products and other forms of interaction A time-interval of 2 hours should be considered between Gaviscon intake and the administration Läs hela dokumentet